Ohr Pharmaceutical

131 articles about Ohr Pharmaceutical

• Ohr Pharma's OHR-102 Fails in Phase II, Shares Plunge

  3/30/2015

• Ohr Pharma Announces Final Topline Data From OHR-102 Phase II IMPACT Study In Wet-AMD

  3/27/2015

• Ohr Pharmaceutical To Present At The 35th Annual Cowen and Company Health Care Conference

  3/3/2015

• Ohr Pharmaceutical Announces Additional Positive Anatomic Data From The OHR-102 IMPACT Study Interim Analysis Presented At Annual Macula Society Meeting

  3/2/2015

• Ohr Pharmaceutical Appoints Avner Ingerman, M.D. As Chief Clinical Office

  2/26/2015

• Ohr Pharmaceutical Announces Closing Of Public Offering Of Common Stock

  2/11/2015

• Ohr Pharmaceutical Reports Fiscal First Quarter 2015 Financial And Business Results

  2/10/2015

• Ohr Pharmaceutical To Present At The 17th Annual BIO CEO & Investor Conference And Leerink Global Healthcare Conference In New York

  2/9/2015

• Ohr Pharmaceutical Prices $25,000,000 Public Offering Of Common Stock

  2/6/2015

• Ohr Pharmaceutical Announces Proposed Public Offering Of Common Stock

  2/6/2015

• Ohr Pharmaceutical Appoints Jason Slakter, MD, Chief Medical Officer, To Board Of Directors

  1/8/2015

• Ohr Pharmaceutical Reports Fiscal Year 2014 Financial and Business Results

  12/23/2014

• Ohr Pharmaceutical To Announce Fiscal 2014 Financial Results And Host Conference Call On Monday, December 22

  12/19/2014

• Ohr Pharmaceutical To Present At The Oppenheimer 25th Annual Healthcare Conference

  12/2/2014

• Ohr Pharmaceutical To Host Key Opinion Leader Meeting And Webcast On October 31 In New York City

  10/27/2014

• Ohr Pharmaceutical Announces New Positive Anatomic And Visual Acuity Data On OHR-102 (Squalamine Eye Drops) IMPACT Study Presented At The 2014 American Academy of Ophthalmology Scientific Meeting

  10/20/2014

• Ohr Pharmaceutical Announces Successful End Of Phase 2 Meeting With The FDA On Squalamine Eye Drops (OHR-102) In Wet AMD

  10/14/2014

• Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations At The 2014 American Academy of Ophthalmology Scientific Meeting

  10/7/2014

• Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations At The Retina Society 47th Annual Scientific Meeting

  9/9/2014

• Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data In Wet-AMD; The IMPACT Study

  8/13/2014